Vimarsana
Biggest News Aggregation in the World

Hoc Analyses News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hoc Analyses. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hoc Analyses Today - Breaking & Trending Today

Text Messages With Financial Incentives for Men With Obesity - Vimarsana News

Text Messages With Financial Incentives for Men With Obesity

This randomized clinical trial assesses whether text messaging combined with financial incentives or text messages alone could help men with obesity lose

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial | Coronavirus (COVID-19) | JAMA - Vimarsana News

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial | Coronavirus (COVID-19) | JAMA

This randomized clinical trial compares the effects of 3 doses of bamlanivimab monotherapy (700 vs 2800 vs 7000 mg) vs combination bamlanivimab and etesevimab v

Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial | JAMA - Vimarsana News

Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial | JAMA

This randomized trial assesses the comparative effectiveness of direct oral anticoagulants vs low-molecular-weight heparin on rate of 6-month recurrence of veno

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial | Infectious Diseases | JAMA - Vimarsana News

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial | Infectious Diseases | JAMA

This open-label randomized trial compares the effect of remdesivir (5 or 10 days) vs standard care on clinical status 11 days after treatment initiation among p

Neurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023 - Vimarsana News

Neurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that it will present new...